Bookmark and Share Email this page Email Print this page Print Pin It
Feed Feed

Arrowhead Pharma makes stock offering

Pasadena, CA-based Arrowhead Pharmaceuticals, which began as Mirus Corp. in Madison in 1995, announced a $267 million public stock offering, according to a corporate release.

The company sold 4.6 million shares of its common stock the week of Dec. 2–6, according to a Wisconsin State Journal story, and most of the proceeds of the sale will go toward general funding and perhaps future acquisitions.

Arrowhead Pharmaceuticals is developing drugs that primarily target liver disease, using RNA interference, a technique that silences disease-causing genes.

Add your comment:
Bookmark and Share Email this page Email Print this page Print Pin It
Feed Feed
Edit ModuleEdit ModuleShow Tags

Events Calendar

Edit ModuleEdit Module
Edit Module